Drug marketing techniques may be risking patient safety

Dec 03, 2008

With new drugs being reviewed by regulatory agencies and then released onto the market faster than ever before, patients' safety is being compromised, warns a study published on bmj.com today.

Dr David Kao from the University of Colorado Health Sciences Center, argues that while drug regulatory bodies are under pressure to make new drugs available more quickly, there are concerns that the deadlines for approving drugs have shifted the focus away from safety.

Kao reviews trends in drug approval times in the United States, and suggests how drug marketing techniques could be used to improve the way new drugs are monitored.

Previous research has shown that drugs approved in the US during the two months before the mandated deadline were more likely to be withdrawn for safety reasons or to carry a warning.

Today's marketing techniques are so sophisticated, says Kao, that once a drug has been approved the products can be released on websites within 90 minutes. He cites the example of Merck's new treatment (sitagliptin) for hyperglycaemia (high blood sugar levels)—within 14 days of approval 188 million patients or 73% of the insured US population had been targeted by the marketing campaign.

The danger with so many people trying a new drug very quickly, argues Kao, is that it can expose large numbers of patients to unknown risks. When Merck's anti-inflammatory drug Vioxx (rofecoxib) was withdrawn from the market for safety reasons it had been available for five years and 20 million patients had been exposed to it.

Regulatory agencies have been criticised for their dependence on drug companies for funding. The agencies often collect fees from drug companies so that they can hire staff to review the drugs more quickly. The European Agency for the Evaluation of Medicinal Products receives 75% of its funding in this way, 43% of the US Food and Drug Administration (FDA) budget is similarly derived, and the UK's Medicines and Healthcare Products Regulatory Agency is completely funded by drug companies.

The author believes that the systems for reporting adverse drug reactions must be improved and suggests using the very same effective drug marketing techniques to do this. For example, laws in the US already compel TV adverts to instruct patients experiencing negative side effects to report their symptoms to the FDA. This could be expanded to include campaigns dedicated to drug safety monitoring.

Kao concludes by saying that the only drug monitoring system that will minimise unknown risks must involve all the key players in healthcare, including doctors, regulatory bodies, drug companies and patients.

Source: British Medical Journal

Explore further: Doctor describes importance of interpretation in patient care

add to favorites email to friend print save as pdf

Related Stories

New tool aids stem cell engineering for medical research

Aug 28, 2014

A Mayo Clinic researcher and his collaborators have developed an online analytic tool that will speed up and enhance the process of re-engineering cells for biomedical investigation. CellNet is a free-use Internet platform ...

Recommended for you

Obesity and stress pack a double hit for health

2 hours ago

If you're overweight, you may be at greater risk for stress-related diseases like type 2 diabetes, cardiovascular disease and cancer, according to a new study by Brandeis University.

Sales influence consumer food shopping habits

4 hours ago

(HealthDay)—Consumers are more likely to buy high-calorie foods (HCF), but not low-calorie foods (LCF) on sale, according to a study published in the U.S. Center for Disease Control and Prevention's Preventing Ch ...

User comments : 0